摘要
目的:探索二妙散(EMS)对脂多糖(LPS)+干扰素(IFN)-γ诱导大鼠骨髓来源巨噬细胞(Macrophage)M1极化及白细胞介素(IL)-4+IL-13诱导M2极化的影响。方法:体外提取大鼠骨髓来源的单核细胞,加巨噬细胞集落刺激因子(M-CSF),诱导成巨噬细胞(F4/80标记),加入LPS+IFN-γ,诱导其向M1型巨噬细胞极化;加入IL-4和IL-13,诱导其向M2型巨噬细胞极化;加入不同浓度二妙散(0.2,0.4,0.8 g·L^-1)作用后,采用免疫荧光分别检测M1(CD68及iNOS标记)及M2(CD206及Arginase标记)表型,检测二妙散对大鼠骨髓来源的巨噬细胞M1/M2极化的影响。结果:与空白组比较,LPS+IFN-γ能显著增加M1的极化(P<0.01),IL-4+IL-13能显著增加M2的极化(P<0.01);与LPS+IFN-γ/IL-4+IL-13组比较,二妙散(0.2,0.4,0.8 g·L^-1)作用24 h对LPS+IFN-γ诱导的M1极化具有明显抑制作用(P<0.05),对IL-4+IL-13诱导的M2极化没有明显影响。结论:二妙散可抑制LPS+IFN-γ诱导的M1极化,而对IL-4+IL-13诱导的M2极化没有影响。
Objective: To explore the effect of Ermiaosan(EMS) on the polarization of M1 by lipopolysaccharide(LPS)+interferon(IFN)-γ and M2 induced by interleukin(IL)-4+IL-13 in rat bone marrowderived macrophages. Method: Macrophages from rat bone marrow were extracted in vitro,stimulated by macrophage colony stimulating factor(M-CSF),induced to macrophages(marked by F4/80),stimulated by LPS+IFN-γ and induced to polarize to M1,while stimulated by IL-4+IL-13 and induced to polarize to M2. After adding different concentrations of EMS(0. 2,0. 4,0. 8 g·L^-1),the phenotypes of M1 and M2 were detected by immunofluorescence,and the effect of EMS on M1(marked by CD68 and iNOS)/M2(marked by CD206 and Arginase) polarization of macrophages from rat bone marrow was detected. Result: Compared with control group,LPS + IFN-γ could increase the polarization of M1(P<0. 01),while IL-4+IL-13 could increase the polarization of M2(P<0. 01);compared with LPS+IFN-γ/IL-4+IL-13 group,EMS(0. 2,0. 4,0. 8 g·L^-1)could inhibit the polarization of M1 induced by LPS+IFN-γ for 24 hours(P<0. 05),but had no significant effect on polarization of M2 induced by IL-4+IL-13. Conclusion: EMS can inhibit M1 polarization induced by LPS+IFN-γ,but has no effect on M2 polarization induced by IL-4+IL-13.
作者
何莲花
覃清霞
王晗
何文成
王庆文
HE Lian-hua;QIN Qing-xia;WANG Han;HE Wen-cheng;WANG Qing-wen(Shenzhen Hospital,Peking University,Shenzhen 518036,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2020年第11期71-77,共7页
Chinese Journal of Experimental Traditional Medical Formulae
基金
深圳市科技计划项目(JCYJ20170307112009204)
广东省中医药局科研项目(20183011)。
